Liquidia Posts Fourth Straight Profitable Quarter with $74.7M Net Income, YUTREPIA Sales Surge
LQDA has more than doubled off its 52-week low of $19.9.
Summary
Liquidia's Q2 2026 10-Q shows $74.7M net income on $170.4M YUTREPIA sales, but ongoing litigation threatens the drug's market presence. Insiders continue to sell heavily.
Key Events · Earnings and Guidance · LQDA
-
Fourth Straight Profitable Quarter
Net income of $74.7 million in Q2 2026, up from a $41.6 million loss a year ago, marking the fourth consecutive profitable quarter.
-
YUTREPIA Sales Surge
Net product sales reached $170.4 million in Q2 2026, compared to $6.5 million in Q2 2025, driven by higher volume following FDA approval in May 2025.
-
Strong Cash Position
Cash and cash equivalents of $284.2 million as of June 30, 2026, up from $190.7 million at year-end 2025, providing sufficient runway for at least 12 months.
-
Existential Litigation Risk
United Therapeutics is seeking injunctive relief in multiple lawsuits that could require YUTREPIA to be removed from the market; a decision in the '327 Patent Litigation is pending.
Analysis · LQDA · Life Sciences
Liquidia delivered Q2 net income of $74.7 million, its fourth consecutive profitable quarter, driven by $170.4 million in YUTREPIA net product sales — a massive ramp from just $6.5 million a year ago. The company holds $284.2 million in cash, providing ample runway, but the 10-Q underscores existential risk: multiple patent and trade secret lawsuits from United Therapeutics seek to remove YUTREPIA from the market entirely. A court decision in the '327 Patent Litigation is pending and could force a label change or market withdrawal. Against that backdrop, two insiders adopted 10b5-1 trading plans during the quarter, adding to a 90-day insider selling trend of nearly $140 million.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $87.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $19.90 to $93.61. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.